Baidu
map

International Journal of Cancer:表观遗传新应用!宫颈癌检测率 100%!

2018-12-19 佚名 转化医学网

导 读 宫颈癌是一种最常见的女性生殖道恶性肿瘤,发病率在女性恶性肿瘤中居第二位,多发于发展中国家,每年有超过 26 万的妇女死于宫颈癌。在推崇精准医疗的当下,宫颈癌的提早检测提早预防是许多研究者的课题,伦敦 Queen Mary 大学的研究者们,在分析了 15744 份女性的临床筛查数据后发现,可以使用一种新的成本较低的基于表观遗传学的检测方法,较为有效的在早期检测宫颈癌。


导  读

宫颈癌是一种最常见的女性生殖道恶性肿瘤,发病率在女性恶性肿瘤中居第二位,多发于发展中国家,每年有超过 26 万的妇女死于宫颈癌。在推崇精准医疗的当下,宫颈癌的提早检测提早预防是许多研究者的课题,伦敦 Queen Mary 大学的研究者们,在分析了 15744 份女性的临床筛查数据后发现,可以使用一种新的成本较低的基于表观遗传学的检测方法,较为有效的在早期检测宫颈癌。

该研究结果发表于 International Journal of Cancer,研究人员没有通过直接检查 DNA 遗传面上是否有 HPV 病毒的常规方法,而将目光投向了 DNA 上会自然出现的化学标记,构建其“表观遗传图谱”,从而可以提前五年对宫颈癌的发展进行预测。

巨大的进步

本次研究的首席研究员,来自伦敦 Queen Mary 大学的 Attila Lorincz 教授说道:“这是一次巨大的进步,除了这项测试检测宫颈癌的能力之外,这还是首次有人利用临床病人的数据证明了表观遗传学在实体瘤癌症的发展中发挥了关键作用,与许多研究人员和医生所说的相反,越来越多的数据表明,驱动包括宫颈癌、口腔癌、直肠癌、前列腺癌等癌症在内的实际上是表观遗传而不是 DNA 的突变。”

现有主流的宫颈癌检测方法是进行宫颈细胞涂片的检查,但不幸的是,这只能检查出大约 50%的前期宫颈癌。更进一步更精准的检测方法则会检测 HPV 病毒 DNA,HPV 病毒也是目前导致宫颈癌的最主要却不直接的原因,精准度会高一些。

然而,这种检查只能检查出病人是否感染了 HPV 病毒而已,对于接下来会不会患上具体的癌症,风险又是多少,仅能提供一个参考。事实上,很多人都会携带有 HPV 病毒,但是却并不会发病,检查结果可能只会对她们造成一些困扰。

预测患癌风险

而如今,由 Queen Mary 大学的研究者们发明的这种新方法拥有更高的准确率,在 15744 名女性的测试中,这种方法成功检测出 8 种侵袭性宫颈癌的几率高达 100%!同时,宫颈细胞涂片仅为四分之一,HPV 检测则再高一些,有 50%。

研究者还进一步对 257 名 HPV 检测呈阳性的女性进行了进一步检测,将她们分成了三组进行对比检测,结果发现可以检测出其中 93% 的癌前病变,而细胞涂片与 HPV 联合检测出的结果为 86%——显然,在癌前检测中,这种表观遗传学方法也具有更高的检出率。

Lorincz 教授对此补充道:“这真的是一个在诊治 HPV 感染人群时的一个巨大进步,它将会彻底改变筛查的手段,我们惊讶于此方法提早发现和预测早期宫颈癌的几率可以高达 100%,虽然在英国全面建立起测试并推广可能还需要五年时间。”

研究者同时还表示,如果可以全面推行开这项技术,那么价格将会比做宫颈细胞涂片还要便宜,患者也将可以减少很多额外的检查。

原始出处:


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2008742, encodeId=db272008e4283, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Mon Jun 17 06:58:00 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883492, encodeId=8d4718834926f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Jul 07 01:58:00 CST 2019, time=2019-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408158, encodeId=d6dc1408158ad, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Fri Dec 21 07:58:00 CST 2018, time=2018-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355901, encodeId=ecc6355901ca, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=88e885554, createdName=wz12888, createdTime=Thu Dec 20 08:02:58 CST 2018, time=2018-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355861, encodeId=0bf03558611a, content=已学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=88e885554, createdName=wz12888, createdTime=Wed Dec 19 17:39:12 CST 2018, time=2018-12-19, status=1, ipAttribution=)]
    2019-06-17 般若傻瓜
  2. [GetPortalCommentsPageByObjectIdResponse(id=2008742, encodeId=db272008e4283, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Mon Jun 17 06:58:00 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883492, encodeId=8d4718834926f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Jul 07 01:58:00 CST 2019, time=2019-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408158, encodeId=d6dc1408158ad, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Fri Dec 21 07:58:00 CST 2018, time=2018-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355901, encodeId=ecc6355901ca, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=88e885554, createdName=wz12888, createdTime=Thu Dec 20 08:02:58 CST 2018, time=2018-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355861, encodeId=0bf03558611a, content=已学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=88e885554, createdName=wz12888, createdTime=Wed Dec 19 17:39:12 CST 2018, time=2018-12-19, status=1, ipAttribution=)]
    2019-07-07 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=2008742, encodeId=db272008e4283, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Mon Jun 17 06:58:00 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883492, encodeId=8d4718834926f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Jul 07 01:58:00 CST 2019, time=2019-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408158, encodeId=d6dc1408158ad, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Fri Dec 21 07:58:00 CST 2018, time=2018-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355901, encodeId=ecc6355901ca, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=88e885554, createdName=wz12888, createdTime=Thu Dec 20 08:02:58 CST 2018, time=2018-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355861, encodeId=0bf03558611a, content=已学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=88e885554, createdName=wz12888, createdTime=Wed Dec 19 17:39:12 CST 2018, time=2018-12-19, status=1, ipAttribution=)]
    2018-12-21 一闲
  4. [GetPortalCommentsPageByObjectIdResponse(id=2008742, encodeId=db272008e4283, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Mon Jun 17 06:58:00 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883492, encodeId=8d4718834926f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Jul 07 01:58:00 CST 2019, time=2019-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408158, encodeId=d6dc1408158ad, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Fri Dec 21 07:58:00 CST 2018, time=2018-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355901, encodeId=ecc6355901ca, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=88e885554, createdName=wz12888, createdTime=Thu Dec 20 08:02:58 CST 2018, time=2018-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355861, encodeId=0bf03558611a, content=已学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=88e885554, createdName=wz12888, createdTime=Wed Dec 19 17:39:12 CST 2018, time=2018-12-19, status=1, ipAttribution=)]
    2018-12-20 wz12888

    学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2008742, encodeId=db272008e4283, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Mon Jun 17 06:58:00 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883492, encodeId=8d4718834926f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Jul 07 01:58:00 CST 2019, time=2019-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408158, encodeId=d6dc1408158ad, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Fri Dec 21 07:58:00 CST 2018, time=2018-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355901, encodeId=ecc6355901ca, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=88e885554, createdName=wz12888, createdTime=Thu Dec 20 08:02:58 CST 2018, time=2018-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355861, encodeId=0bf03558611a, content=已学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=88e885554, createdName=wz12888, createdTime=Wed Dec 19 17:39:12 CST 2018, time=2018-12-19, status=1, ipAttribution=)]
    2018-12-19 wz12888

    已学习

    0

相关资讯

Cell:突破现有认识局限,发现肿瘤表观遗传靶点新机制

这一研究的发现突破现有认识局限,有望将EZH2抑制剂的应用推广到EZH2高表达的实体肿瘤,极大地拓展了这类抑制剂的临床应用空间。

Blood:北美ATLL患者具有独特的突变和表观遗传图谱,有望采用表观遗传治疗

中心点:北美ATLL患者具有独特的遗传图谱,携带高频的与预后相关的表观遗传突变,包括EP300突变。携带EP300的ATLL样本,p53功能受损,对地西他滨治疗敏感性多变。摘要:成人T细胞白血病淋巴瘤(ATLL)是一种罕见的T细胞肿瘤,好发于日本、加勒比海和拉丁美洲人群。大部分北美ATLL患者为加勒比人后裔,与日本ATLL患者相比,其特征为化疗耐受性疾病发病率高、预后差。为明确两个队列的遗传差异,

PLOS BIOL:耶鲁严钦组报道调控肿瘤免疫逃逸的表观遗传新机制

在机体正常细胞发展为癌细胞的过程中积累许多变化,导致癌细胞通常具有比较强的免疫原性。人体的各种先天性与获得性免疫机制可以识别这些非正常的细胞,从而在癌发展的早期将其清除,避免癌症的发生。只有通过一定的机制逃避了这些抗癌的免疫反应,癌才得以形成。这一过程被称为肿瘤的免疫逃逸。近十年来,癌细胞的免疫逃逸机制,以及针对这些机制的免疫再激活策略成为癌症新疗法的研究重点。例如最近非常热的免疫检验点疗法,就是

Pediatrics:母乳喂养改善婴儿表观遗传

长期以来,人们一直认为,母乳喂养对母亲和婴儿有许多生理和心理健康益处,这些益处是由于母乳喂养引起的遗传变化吗?一项新研究证明了这种关联。

J Neurosci:改善记忆,从表观遗传调控入手

阿拉巴马大学的研究人员在《Journal of Neuroscience》上发表研究,找到了将表观遗传变化与翻译控制变化联系起来的新机制。文章报道,在恐惧记忆再巩固过程中,大鼠海马中几种特殊的表观遗传变化通过Pten基因控制大脑神经元下游翻译调节。受PTEN酶水平影响,下游靶标AKT-mTOR途径,它是参与记忆再巩固最主要的翻译控制途径之一。

Brit J Cancer:准确率达92%!甲基化助力前列腺癌诊断!

前列腺癌(PCa)是老年男性最高发的恶性肿瘤之一,在我国,该病发病率正在快速增长。前列腺癌被称为“沉默的杀手”,不甚明朗的肿瘤分期极易造成“过度治疗”,也可导致疾病进展时的措手不及或无效治疗,因此,找寻可准确分辨前列腺癌真正状态的标志物成为了当务之急。近日,英国和加拿大的科学家们确定了一种可检测的DNA甲基化标记,他们声称该方法可以区分前列腺癌的“侵袭”和“可治”状态,准确率高达92%。换言之,前

Baidu
map
Baidu
map
Baidu
map